BR112022018070A2 - Métodos e composições relacionados a nanoveículos sintéticos - Google Patents
Métodos e composições relacionados a nanoveículos sintéticosInfo
- Publication number
- BR112022018070A2 BR112022018070A2 BR112022018070A BR112022018070A BR112022018070A2 BR 112022018070 A2 BR112022018070 A2 BR 112022018070A2 BR 112022018070 A BR112022018070 A BR 112022018070A BR 112022018070 A BR112022018070 A BR 112022018070A BR 112022018070 A2 BR112022018070 A2 BR 112022018070A2
- Authority
- BR
- Brazil
- Prior art keywords
- synthetic
- nanovehicles
- methods
- compositions related
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Materials Engineering (AREA)
- Composite Materials (AREA)
- Manufacturing & Machinery (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062988347P | 2020-03-11 | 2020-03-11 | |
| PCT/US2021/021939 WO2021183781A1 (en) | 2020-03-11 | 2021-03-11 | Methods and compositions related to synthetic nanocarriers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022018070A2 true BR112022018070A2 (pt) | 2022-10-25 |
Family
ID=75439463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022018070A BR112022018070A2 (pt) | 2020-03-11 | 2021-03-11 | Métodos e composições relacionados a nanoveículos sintéticos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210308058A1 (enExample) |
| EP (1) | EP4117631A1 (enExample) |
| JP (1) | JP2023518192A (enExample) |
| KR (1) | KR20220152263A (enExample) |
| CN (1) | CN115484931A (enExample) |
| AU (1) | AU2021236234A1 (enExample) |
| BR (1) | BR112022018070A2 (enExample) |
| CA (1) | CA3174988A1 (enExample) |
| IL (1) | IL296326A (enExample) |
| MX (1) | MX2022011248A (enExample) |
| WO (1) | WO2021183781A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140041505A (ko) | 2011-04-29 | 2014-04-04 | 셀렉타 바이오사이언시즈, 인크. | 조절 b 세포 유도를 위한 관용원성 합성 나노운반체 |
| BR112015027291A8 (pt) | 2013-05-03 | 2019-12-24 | Selecta Biosciences Inc | uso de um imunossupressor que têm uma vida eficaz farmacodinâmica especificada e composição compreendendo o referido imunossupressor |
| WO2016037164A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses |
| KR102753928B1 (ko) | 2017-03-11 | 2025-01-14 | 셀렉타 바이오사이언시즈, 인크. | 항염증제, 및 면역억제제를 포함하는 합성 나노담체를 사용한 조합 치료와 관련된 방법 및 조성물 |
| EP3980784A1 (en) | 2019-06-04 | 2022-04-13 | Selecta Biosciences, Inc. | Formulations and doses of pegylated uricase |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946929A (en) | 1983-03-22 | 1990-08-07 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
| US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
| US4806621A (en) | 1986-01-21 | 1989-02-21 | Massachusetts Institute Of Technology | Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article |
| US5804178A (en) | 1986-11-20 | 1998-09-08 | Massachusetts Institute Of Technology | Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue |
| US5736372A (en) | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
| CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
| US5019379A (en) | 1987-07-31 | 1991-05-28 | Massachusetts Institute Of Technology | Unsaturated polyanhydrides |
| US5010167A (en) | 1989-03-31 | 1991-04-23 | Massachusetts Institute Of Technology | Poly(amide-and imide-co-anhydride) for biological application |
| US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
| US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
| US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| US5716404A (en) | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
| US6123727A (en) | 1995-05-01 | 2000-09-26 | Massachusetts Institute Of Technology | Tissue engineered tendons and ligaments |
| US6095148A (en) | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
| DE19545257A1 (de) * | 1995-11-24 | 1997-06-19 | Schering Ag | Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln |
| US5902599A (en) | 1996-02-20 | 1999-05-11 | Massachusetts Institute Of Technology | Biodegradable polymer networks for use in orthopedic and dental applications |
| US6258823B1 (en) | 1996-07-12 | 2001-07-10 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| US7288266B2 (en) | 1996-08-19 | 2007-10-30 | United States Of America As Represented By The Secretary, Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
| US5837752A (en) | 1997-07-17 | 1998-11-17 | Massachusetts Institute Of Technology | Semi-interpenetrating polymer networks |
| US6187335B1 (en) | 1997-12-31 | 2001-02-13 | Orasomal Technologies, Inc. | Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom |
| US6632922B1 (en) | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| US6506577B1 (en) | 1998-03-19 | 2003-01-14 | The Regents Of The University Of California | Synthesis and crosslinking of catechol containing copolypeptides |
| US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| WO2000006120A1 (en) | 1998-07-31 | 2000-02-10 | Korea Institute Of Science And Technology | Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier |
| EP1267946A4 (en) | 2000-02-28 | 2008-07-02 | Genesegues Inc | SYSTEM AND METHOD FOR ENCAPSULATING NANOCAPSULES |
| WO2003020797A1 (en) | 2001-08-30 | 2003-03-13 | The Regents Of The University Of California | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers |
| WO2004017943A2 (en) | 2002-08-23 | 2004-03-04 | Medigene Oncology Gmbh | Non-vesicular cationic lipid formulations |
| US20050260260A1 (en) | 2004-05-19 | 2005-11-24 | Edward Kisak | Liposome compositions for the delivery of macromolecules |
| CA2917512C (en) | 2007-10-12 | 2025-08-05 | President And Fellows Of Harvard College | VACCINE NANOTECHNOLOGY |
| CN101676291B (zh) | 2008-09-18 | 2012-05-09 | 上海海和药物研究开发有限公司 | 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途 |
| KR101267813B1 (ko) * | 2009-12-30 | 2013-06-04 | 주식회사 삼양바이오팜 | 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물 |
| AU2012323937A1 (en) | 2011-10-14 | 2014-06-05 | Stc.Unm | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof |
| AU2013315125B2 (en) * | 2012-09-17 | 2018-07-26 | Pfizer Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
| TWI679019B (zh) * | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物 |
| US20150359865A1 (en) * | 2014-06-17 | 2015-12-17 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers for t-cell-mediated autoimmune disease |
| FI3834823T3 (fi) * | 2014-11-05 | 2024-04-02 | Cartesian Therapeutics Inc | Menetelmiä ja koostumuksia liittyen alhaisen hlb:n omaavien pinta-aktiivisten aineiden käyttöön rapalogin käsittävien synteettisten nanokantajien valmistuksessa |
| WO2017031368A1 (en) * | 2015-08-18 | 2017-02-23 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| WO2017138983A1 (en) * | 2016-02-10 | 2017-08-17 | Pfizer Inc. | Therapeutic nanoparticles having egfr ligands and methods of making and using same |
| GB201608323D0 (en) * | 2016-05-12 | 2016-06-29 | Ucb Biopharma Sprl | Pharmaceutical compositions |
| US11583504B2 (en) * | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| WO2019162951A1 (en) * | 2018-02-26 | 2019-08-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Drug delivery systems |
| CN112057425A (zh) * | 2020-09-30 | 2020-12-11 | 严鹏科 | 一种雷帕霉素制剂及其制备方法 |
-
2021
- 2021-03-11 AU AU2021236234A patent/AU2021236234A1/en active Pending
- 2021-03-11 JP JP2022554953A patent/JP2023518192A/ja active Pending
- 2021-03-11 CN CN202180032088.3A patent/CN115484931A/zh active Pending
- 2021-03-11 BR BR112022018070A patent/BR112022018070A2/pt unknown
- 2021-03-11 IL IL296326A patent/IL296326A/en unknown
- 2021-03-11 KR KR1020227034578A patent/KR20220152263A/ko active Pending
- 2021-03-11 WO PCT/US2021/021939 patent/WO2021183781A1/en not_active Ceased
- 2021-03-11 US US17/199,130 patent/US20210308058A1/en active Pending
- 2021-03-11 CA CA3174988A patent/CA3174988A1/en active Pending
- 2021-03-11 EP EP21717616.3A patent/EP4117631A1/en active Pending
- 2021-03-11 MX MX2022011248A patent/MX2022011248A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115484931A (zh) | 2022-12-16 |
| MX2022011248A (es) | 2022-12-15 |
| IL296326A (en) | 2022-11-01 |
| AU2021236234A1 (en) | 2022-10-06 |
| CA3174988A1 (en) | 2021-09-16 |
| US20210308058A1 (en) | 2021-10-07 |
| EP4117631A1 (en) | 2023-01-18 |
| WO2021183781A1 (en) | 2021-09-16 |
| JP2023518192A (ja) | 2023-04-28 |
| KR20220152263A (ko) | 2022-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022011248A (es) | Metodos y composiciones relacionados con nanoportadores sinteticos. | |
| BR112017000024A2 (pt) | composição para tratamento de tecidos que compreende uma nanoemulsão polimérica de aminossiloxano | |
| BR112018004620A2 (pt) | moduladores da expressão de kras | |
| BR112015010104A2 (pt) | Variante de enzima termolisina, composição e método de limpeza | |
| MY204607A (en) | Bitumen compositions comprising lignin | |
| BR112018007982A2 (pt) | composição, reação enzimática e método para preparar um copolímero de enxerto | |
| EA201001639A1 (ru) | Композиции и способы их получения и применения | |
| BR112018009235A8 (pt) | composição de aditivo alimentar | |
| EA201492160A1 (ru) | Композиции, содержащие бензодиазепины короткого действия | |
| BR112017010868A2 (pt) | composição adoçante | |
| EA201100865A1 (ru) | Композиции со сниженным образованием димеров | |
| BR112016017509A2 (pt) | composições e métodos compreendendo uma variante da enzima xilanase | |
| MX339060B (es) | Formulaciones del factor viii. | |
| EP4233771A3 (en) | Vulcanization composition having reduced allergenic potential | |
| BR112015008419A2 (pt) | composição imunogênica, e, vacina | |
| BR112023018344A2 (pt) | Composições de cimento, e métodos das mesmas | |
| JOP20170128A1 (ar) | عوامل ارتباط عكسية للأجسام المضادة الموجهة ضد عامل التجلط XI/XIa واستخداماتها | |
| BR112018006368A2 (pt) | composição para desempenho melhorado | |
| EA200970377A1 (ru) | Композиции фенилалкиламинокарбамата | |
| BR112015006543A2 (pt) | misturas de esteviosídeos | |
| BR112015023387A2 (pt) | composições lipídicas de racecodotril | |
| BR112019018088A2 (pt) | Composições propositadamente selecionadas que compreendem canabinoides purificados e/ou terpenos purificados | |
| BR112014016220A8 (pt) | composição e artigo | |
| MX392977B (es) | Composiciones y metodos para programar celulas terapeuticas utilizando nanoportadores de acidos nucleicos dirigidos. | |
| BR112017017069A2 (pt) | composições de polímero termoplástico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |